Navigation Links
AIDS study challenges conventional treatment guidelines for HIV patients

n individual patient's CD4 cell loss rate can be explained by his or her presenting viral load. Moreover, the results were remarkably similar when the analyses were reproduced separately in each of the two cohorts, and changed only minimally when the investigators considered the possible effect of errors in the measurement of the CD4 cell count and the HIV viral load.

These results represent a shift in the paradigm that the rate of CD4 cell loss in a given HIV-infected individual can be accurately predicted by his or her viral load. Predicting disease progression is crucial in the treatment of HIV-positive people, such as in making the decision as to when it is best for starting antiretroviral therapy. Current treatment guidelines, while diminishing its importance, continue to include HIV viral load as one element in making decisions regarding when to begin antiretroviral therapy. Antiretroviral therapy, also known as HAART, is credited with saving millions of lives. However, potent side effects and issues of drug resistance, often cause doctors and patients to defer starting the medications, until it becomes medically necessary.

In addition to the clinical ramifications, the findings suggest that HIV-associated CD4 depletion cannot be thought of as a mere consequence of the amount of virus circulating in the blood. Instead, the findings suggest rather more complex scenarios of disease progression, and hint at indirect processes though which HIV can induce damage to the immune system, which cannot be adequately captured by measuring HIV levels in the blood.
'"/>

Source:University Hospitals of Cleveland


Page: 1 2 3

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis

Post Your Comments:
(Date:12/2/2009)...anpei Suzuki Diabetes Foundation is pleased to ann...Donald F. Steiner, MD, A. N. Pritzker Distinguishe...ine and Biochemistry and Molecular Biology, The Un...urated in 2008 to commemorate the 15th anniversary...g those who have enlightened researchers in the fi...
(Date:12/2/2009)...ore one of your muscles can twitch, before the tho...a tiny floodgate of sortscalled an ion channelmust...to let in the chemical signals that spur the cell ... of Standards and Technology (NIST) has allowed sc...e membrane for the first time, potentially offerin...
(Date:12/2/2009)...c. 2, 2009) HOBOKEN, NJ According to the Nationa... Americans diagnosed with diabetes already have so...pathy, damage to the retina caused by leaky blood ...ith diabetes and is one of the most feared diabeti... patients who,ve had diabetes for 10 years or more...
Breaking Biology News(10 mins):Nervy research: Researchers take initial look at ion channels in a model system 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 3RetireSafe to Senate 3A Stop Proposed Rationing of High Quality Hospital Care Medicare Needs More Physician Hospitals 58219 1RetireSafe to Senate 3A Stop Proposed Rationing of High Quality Hospital Care Medicare Needs More Physician Hospitals 58219 2I Therapeutix Inc Announces Company Name Change 58217 1President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 1President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 2President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 3President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 4President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 5President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 6President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 7President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 8President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 9
...is available in French . , Researchers at McGill... Institute of the Jewish General Hospital along w... Ottawa Health Research Institute (OHRI) report a ...target and destroy cancer cells, a field known as ...d in the September early edition of the Proceedin...
...mmune system signaling and the production of speci...me primates are able to live with an immunodeficie...ke illness, unlike other primate species, includin...ase. , Following the identification of HIV (Huma...years ago, an extensive search was undertaken to i...
...- Stephen Smiley, Ph.D., a member of the scientifi... could lead to new treatments for several common d...e National Institutes of Health (NIH) for nearly $...atory are working to develop treatments for a numb...od coagulation pathways causes damage to the body....
Other Biology News:Viral 'magic bullet' targets cancer cells with help of new compound 2Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS 2Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS 3Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS 4Multiple disease-related research gets green light from the NIH 2
(Date:12/2/2009)...SINGAPORE, Dec. 2 S*BIO Pte Ltd to... JAK2 inhibitor, SB1518, at The American Society o... New Orleans. ,, Data will be presented on the ...trial of SB1518 detailing its safety, tolerability...le in dose levels ranging from 100 to 600 mg. Thes...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world i...n turmoil and uncertainty is part of many,business...dustry has been,relatively immune to the economic ... , During the midst of the difficult time...; Johnson inaugurated an R&D center in Shangha...
(Date:12/1/2009)... VILLAGE, Nev., Dec. 1 P...nounced revenue guidance for the fourth quarter en..., as compared with $69 million for the fourth quar...ts was the first of two installment payments of $1... quarter 2008 results was a one-time $1.8 million ...
(Date:12/1/2009)...TH, Mass., Dec. 1 Harvest Technolo... results from the company sponsored 60-patient cli...enter in Chennai, India using the company,s BMAC S...ritical Limb Ischemia (CLI). Sri Ramachandra Medic...iated institution based in Chennai, India and one ...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...g Term Development Agreement to Produce Reference ...e Cancer Research, NEWARK, Del., April 3, 2008 S...ader in providing advanced antibody,products and s...at it has,been selected by Science Applications In...evelop monoclonal antibodies for the Proteomics Re...
... Conditions to the Tender Offer Have Been Satisfie...,Investments Ltd. (TASE: CII) announced today that... previously-announced tender offer to purchase,up ...daq: FNDT )(TASE: FNDT),at $12.50 per share, net ...ng taxes and without interest. Clal Industries has...
...enerative Medicine leader to expand space and empl... square feet for new global ... Joined by local officials,and Organogenesis, Inc...nced today that the Massachusetts-based company, w...ide of the state, is initiating an,expansion of it...
Other Biology Technology:Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research 2Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research 3Clal Industries Commences Additional Offer Period for Fundtech Tender Offer 2Clal Industries Commences Additional Offer Period for Fundtech Tender Offer 3Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters 2Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters 3Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters 4
Hybridization Buffer from BD Biosciences Pharmingen
Chicken Anti-Plants Thaumatin 2 Polyclonal Antibody, Unconjugated from Abcam
Proteinase K Buffer from BD Biosciences Pharmingen
Rabbit Anti-VEGF Receptor 2, phospho (Tyr1214) Polyclonal Antibody, Unconjugated from Abcam
Biology Products: